Traditional clinical trial designs often delay progress due to rigid protocols and frequent amendments. Adaptive and platform trial models introduce flexibility and shared infrastructure, reducing startup delays, cutting costs, and enabling sponsors to conduct faster, more efficient research.
Oncology research continues to push scientific boundaries, from biomarker-driven therapies to increasingly personalized treatment strategies. Operationally, however, many oncology trials
Oncology clinical trials are becoming increasingly complex, placing new operational and administrative demands on both sponsors and research sites. Protocols
In this webinar, leaders from cancer centers and biopharma companies will discuss the operational and institutional hurdles sites face and what can be done to address them. The panel will explore practical strategies to reduce burden, improve collaboration, and create a better experience for research staff and patients alike.
Join experts from Johnson & Johnson Innovative Medicine, Bayer, The START Center for Cancer Care, and Advarra to discuss the ethical use of real-world data in clinical research.
Making Just-in-Time Oncology Trials Work: Overcoming Barriers and Unlocking Potential As part of Oncology Research Pulse, our new thought leadership
AACI/CCAF Annual Meeting Network with cancer center colleagues, groups, and health agencies to develop solutions to common challenges.
2025 ASCO Annual Meeting This conference will bring leading oncology professionals together to connect, inspire, and collaborate.
SCRS Oncology Site Solutions Summit Collaborate with research sites, sponsors, CROs, and solution at the SCRS Oncology Site Solutions Summit
Oncology trials face unique hurdles in innovation, enrollment, and endpoints, requiring strategic planning to address complex study demands and precision needs.
Phase I oncology trials present distinct ethical challenges, such as participant vulnerability and the risk of therapeutic misconception, requiring careful oversight.
Diversity, equity, and inclusion (DEI) are critical pillars in the evolving landscape of cancer research. These values not only
